Related Experiment Video
Updated: Jun 27, 2026
05:31
Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
Published on: January 26, 2024
Association between von Willebrand factor gene polymorphism and preeclampsia
Chengjuan Sun1, Ying Chen, Weiyuan Zhang
1Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, People's Republic of China.
Journal of Perinatal Medicine
|November 22, 2008
Summary
The Msp I polymorphism in the von Willebrand factor gene is linked to preeclampsia development and severity in the Chinese Han population, suggesting it as a potential susceptibility factor.
Area of Science:
- Genetics
- Obstetrics
- Molecular Biology
Background:
- Preeclampsia is a serious pregnancy complication.
- The von Willebrand factor (vWF) gene plays a role in hemostasis.
- Genetic variations may influence preeclampsia susceptibility.
Purpose of the Study:
- To investigate the association between the Msp I polymorphism in the vWF gene (intron 19) and preeclampsia in the Chinese Han population.
- To determine if this polymorphism correlates with preeclampsia severity.
Main Methods:
- A case-control study involving 70 preeclampsia patients and 82 normal pregnancies.
- Genotyping of the Msp I polymorphism in the vWF intron 19 gene using PCR-RFLP and direct sequencing.
Main Results:
- The M+ allele frequency was significantly higher in preeclampsia patients (45.7%) compared to normal pregnancies (19.5%).
- Genotype frequencies differed significantly between the two groups.
Conclusions:
- The Msp I polymorphism (M+ allele) in the vWF gene is associated with preeclampsia development.
- This polymorphism may serve as a susceptibility factor for preeclampsia and its severity.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:43Incomplete Dominance
Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...